Ganesh Moorthy

651 total citations
22 papers, 453 citations indexed

About

Ganesh Moorthy is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ganesh Moorthy has authored 22 papers receiving a total of 453 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 9 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ganesh Moorthy's work include PI3K/AKT/mTOR signaling in cancer (6 papers), PARP inhibition in cancer therapy (6 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Ganesh Moorthy is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (6 papers), PARP inhibition in cancer therapy (6 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Ganesh Moorthy collaborates with scholars based in United States, United Kingdom and Australia. Ganesh Moorthy's co-authors include Daniel K. Benjamin, P. Brian Smith, Michael Cohen‐Wolkowiez, Ira M. Cheifetz, Kelly C. Wade, Pankaj B. Desai, John C. Morris, Mohamad A. Salkeni, Nagla Abdel Karim and Sara C. Kozma and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Ganesh Moorthy

22 papers receiving 444 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ganesh Moorthy United States 10 189 154 97 74 71 22 453
Qun Hu China 11 278 1.5× 137 0.9× 65 0.7× 63 0.9× 19 0.3× 78 628
Mark Zorbas United States 12 113 0.6× 116 0.8× 43 0.4× 57 0.8× 94 1.3× 23 446
Risto S Cvetkovi New Zealand 8 91 0.5× 137 0.9× 54 0.6× 15 0.2× 43 0.6× 9 506
Ashley E. Glode United States 11 79 0.4× 182 1.2× 42 0.4× 40 0.5× 17 0.2× 28 420
Jiang Wang China 10 121 0.6× 107 0.7× 55 0.6× 12 0.2× 34 0.5× 46 425
Kathleen Deiteren Belgium 9 80 0.4× 86 0.6× 23 0.2× 49 0.7× 46 0.6× 13 320
Yifeng Tao China 14 190 1.0× 90 0.6× 81 0.8× 12 0.2× 16 0.2× 37 512
Stephanie J. Gros Germany 16 272 1.4× 362 2.4× 145 1.5× 23 0.3× 39 0.5× 41 698
Shih-Hsin Hsiao Taiwan 13 202 1.1× 199 1.3× 204 2.1× 26 0.4× 27 0.4× 29 491
Sabine Plasschaert Netherlands 9 181 1.0× 207 1.3× 40 0.4× 10 0.1× 39 0.5× 25 431

Countries citing papers authored by Ganesh Moorthy

Since Specialization
Citations

This map shows the geographic impact of Ganesh Moorthy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ganesh Moorthy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ganesh Moorthy more than expected).

Fields of papers citing papers by Ganesh Moorthy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ganesh Moorthy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ganesh Moorthy. The network helps show where Ganesh Moorthy may publish in the future.

Co-authorship network of co-authors of Ganesh Moorthy

This figure shows the co-authorship network connecting the top 25 collaborators of Ganesh Moorthy. A scholar is included among the top collaborators of Ganesh Moorthy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ganesh Moorthy. Ganesh Moorthy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Moorthy, Ganesh, et al.. (2024). Abstract No. 98 Outcomes of Prostate Artery Embolization Following Failure of Prostatic Urethral Lift (UroLift): A Case-Control Study. Journal of Vascular and Interventional Radiology. 35(3). S44–S44. 1 indexed citations
2.
Hamilton, Erika, Judy S. Wang, Amit M. Oza, et al.. (2023). First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma. Molecular Cancer Therapeutics. 22(10). 1154–1165. 14 indexed citations
3.
Moorthy, Ganesh, Gayle P. Pouliot, Lorraine Graham, et al.. (2023). Comprehensive clinical pharmacology characterization of AZD4635 in healthy participants to support dosing considerations. British Journal of Clinical Pharmacology. 89(9). 2775–2787. 3 indexed citations
4.
Azad, Arun, Mark Voskoboynik, Anthony M. Joshua, et al.. (2023). Phase 1/2a study of AZD5305, a novel poly(adenosine diphosphate ribose) polymerase (PARP) 1-selective inhibitor in combination with new hormonal agents (NHAs) in patients (pts) with metastatic prostate cancer (mPC).. Journal of Clinical Oncology. 41(6_suppl). TPS296–TPS296. 2 indexed citations
5.
Lim, Emerson A., Johanna C. Bendell, Gerald S. Falchook, et al.. (2022). Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors. Clinical Cancer Research. 28(22). 4871–4884. 55 indexed citations
6.
Yap, Timothy A., Seock‐Ah Im, Alison M. Schram, et al.. (2022). Abstract CT007: PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations. Cancer Research. 82(12_Supplement). CT007–CT007. 52 indexed citations
7.
Moorthy, Ganesh, Gayle P. Pouliot, Lorraine Graham, et al.. (2020). Abstract CT168: Clinical pharmacology of AZD4635 (A2ARi): Integration of PK data from cancer patients (CP) and healthy volunteer (HV) clinical trials to provide dosing recommendations. Cancer Research. 80(16_Supplement). CT168–CT168. 1 indexed citations
8.
Vita, Serena De, Janet L. Karlix, Carl Cook, et al.. (2019). First-in-human study of AZD5153, a small molecule inhibitor of bromodomain protein 4 (BRD4), in patients (pts) with relapsed/refractory (RR) malignant solid tumor and lymphoma: Preliminary data.. Journal of Clinical Oncology. 37(15_suppl). 3085–3085. 17 indexed citations
9.
Bendell, Johanna C., Todd M. Bauer, Manish R. Patel, et al.. (2019). Abstract CT026: Evidence of immune activation in the first-in-human Phase Ia dose escalation study of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced solid tumors. Cancer Research. 79(13_Supplement). CT026–CT026. 20 indexed citations
10.
Zhou, Diansong, Terry Podoll, Yan Xu, et al.. (2019). Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach. CPT Pharmacometrics & Systems Pharmacology. 8(7). 489–499. 39 indexed citations
11.
Wise‐Draper, Trisha M., Ganesh Moorthy, Mohamad A. Salkeni, et al.. (2017). A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies. Targeted Oncology. 12(3). 323–332. 95 indexed citations
12.
13.
14.
Wise‐Draper, Trisha M., Ganesh Moorthy, Mohamad A. Salkeni, et al.. (2015). A Dose Escalation Single Arm Phase Ib Combination Study of BEZ235 with Everolimus in Patients with Advanced Solid Malignancies. Annals of Oncology. 26. ii16–ii16. 1 indexed citations
15.
Moorthy, Ganesh, et al.. (2015). Safety, tolerability and pharmacokinetics of 2‐pyridylacetic acid, a major metabolite of betahistine, in a phase 1 dose escalation study in subjects with ADHD. Biopharmaceutics & Drug Disposition. 36(7). 429–439. 9 indexed citations
16.
Stockmann, Chris, Yu Tian, Jonathan E. Constance, et al.. (2015). Renal Function Descriptors in Neonates: Which Creatinine‐Based Formula Best Describes Vancomycin Clearance?. The Journal of Clinical Pharmacology. 56(5). 528–540. 7 indexed citations
17.
Salkeni, Mohamad A., Olivier Rixe, Nagla Abdel Karim, et al.. (2013). BEZ235 in combination with everolimus for advanced solid malignancies: Preliminary results of a phase Ib dose-escalation study.. Journal of Clinical Oncology. 31(15_suppl). e13518–e13518. 6 indexed citations
18.
Watt, Kevin, Daniel K. Benjamin, Ira M. Cheifetz, et al.. (2012). Pharmacokinetics and Safety of Fluconazole in Young Infants Supported With Extracorporeal Membrane Oxygenation. The Pediatric Infectious Disease Journal. 31(10). 1042–1047. 38 indexed citations
19.
Salkeni, Mohamad A., Muhammad Shaalan Beg, Hassana Fathallah, et al.. (2012). A dose escalation, single arm, phase Ib/II combination study of BEZ235 with everolimus to determine the safety, pharmacodynamics, and pharmacokinetics in subjects with advanced solid malignancies including glioblastoma multiforme.. Journal of Clinical Oncology. 30(15_suppl). TPS3116–TPS3116. 3 indexed citations
20.
Smith, P. Brian, Christoph P. Hornik, Ira M. Cheifetz, et al.. (2010). Fluconazole Loading Dose Pharmacokinetics and Safety in Infants. The Pediatric Infectious Disease Journal. 30(5). 375–378. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Qun Hu Breakdown of academic impact, for papers by Mark Zorbas Breakdown of academic impact, for papers by Risto S Cvetkovi Breakdown of academic impact, for papers by Ashley E. Glode Breakdown of academic impact, for papers by Jiang Wang Breakdown of academic impact, for papers by Kathleen Deiteren Breakdown of academic impact, for papers by Yifeng Tao Breakdown of academic impact, for papers by Stephanie J. Gros Breakdown of academic impact, for papers by Shih-Hsin Hsiao Breakdown of academic impact, for papers by Sabine Plasschaert
Rankless by CCL
2026